INEX Innovate bags COVID-19 Management Initiative of the Year - Singapore award

The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.

INEX Innovate took home the COVID-19 Management Initiative of the Year - Singapore trophy at the recently concluded Healthcare Asia Medtech Awards. The awards programme aims to recognise medtech companies that have made a remarkable impact on their clients and patients.

INEX Innovate is a Singaporean molecular diagnostics group specialising in prenatal, infectious diseases and oncology diagnostics. Since the onset of the pandemic, the group has pivoted into COVID-19 testing and stepped up by rapidly increasing testing capacity to support the nation in its fight against COVID-19.

iGene Laboratory, INEX Innovate’s wholly owned subsidiary company, has become one of the few private laboratories licensed by the Ministry of Health to run COVID-19 tests ramping up capacity to service thousands of patients per day. The team’s efficiency and business flexibility enabled the procurement of advanced equipment, hiring of certified laboratory technicians, and adapting new technologies to improve overall operational efficiency. INEX additionally offers CORO® COVID-19 Real-Time RT-PCR test kit to local and regional laboratories. CORO® has been granted Singapore Health Sciences Authority (HSA) Provisional Authorization.

Aside from these accomplishments, INEX Innovate has recently launched Rhene®, Asia’s first Non-Invasive Prenatal Test (NIPT) for fetal RhD Status which is used to non-invasively predict the RhD Status of a fetus by analysing Cell-Free Fetal DNA (cffDNA) in the maternal plasma. The NIPT RHD test is recommended in pregnancies where the mother is RhD negative, and the fetus is at risk of being affected by Haemolytic Disease of the Newborn (HDN). The launch of the test has supported the local network of OBGYN doctors the company has been serving for years. 

Moreover, INEX has been developing new medical device products such as OvaCis®, an intro-operative point-of-care rapid test to distinguish between benign and malignant ovarian cancer within 15 minutes, XENA® a non-invasive liquid biopsy test based on cell-free MicroRNA biomarkers technology for the detection of ovarian cancer. Moreover, epiDX® Bc a liquid biopsy test for the diagnosis of breast cancer utilizing epigenetic targets associated with breast cancer in Asian women.   The robust product portfolio in oncology and pre-natal healthcare space has enabled brand recognition and diversified recurring income stream. 

INEX Innovate’s competitiveness is also underpinned by strategic partnerships and collaborations with global centres of medical excellence in Singapore and across the globe with JVs in China, Indonesia and USA.

The initiatives undertaken by INEX highlights the unique value that it delivers and its passion to improve health for people across the world.